BRAF and breast carcinoma: Trastuzumab and pertuzumab target different domains of the HER2 receptor and form a standard treatment for HER2-positive breast cancer (Jagosky and Tan, 2021), while BRAF and MEK inhibitors are co-administered to treat BRAF-mutated metastatic melanoma, improving outcomes and reducing toxicity (Eroglu and Ribas, 2016).